131 related articles for article (PubMed ID: 20586520)
1. Financial and clinical characteristics of fibromyalgia: a case-control comparison.
Palacio A; Uribe CL; Li H; Hanna J; Deminski M; Alvir J; Chandran A; Sanchez R
Am J Manag Care; 2010 May; 16(5 Suppl):S118-25. PubMed ID: 20586520
[TBL] [Abstract][Full Text] [Related]
2. Patterns of healthcare utilization and cost in patients with newly diagnosed fibromyalgia.
Berger A; Sadosky A; Dukes EM; Edelsberg J; Zlateva G; Oster G
Am J Manag Care; 2010 May; 16(5 Suppl):S126-37. PubMed ID: 20586521
[TBL] [Abstract][Full Text] [Related]
3. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
4. Impact of a step-therapy protocol for pregabalin on healthcare utilization and expenditures in a commercial population.
Udall M; Louder A; Suehs BT; Cappelleri JC; Joshi AV; Patel NC
J Med Econ; 2013; 16(6):784-92. PubMed ID: 23565813
[TBL] [Abstract][Full Text] [Related]
5. Clinical comorbidities, treatment patterns, and direct medical costs of patients with osteoarthritis in usual care: a retrospective claims database analysis.
Gore M; Tai KS; Sadosky A; Leslie D; Stacey BR
J Med Econ; 2011; 14(4):497-507. PubMed ID: 21682606
[TBL] [Abstract][Full Text] [Related]
6. Initial use of pregabalin, patterns of pain-related pharmacotherapy, and healthcare resource use among older patients with fibromyalgia.
Gore M; Sadosky A; Zlateva G; Clauw D
Am J Manag Care; 2010 May; 16(5 Suppl):S144-53. PubMed ID: 20586523
[TBL] [Abstract][Full Text] [Related]
7. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
[TBL] [Abstract][Full Text] [Related]
8. The London Fibromyalgia Epidemiology Study: direct health care costs of fibromyalgia syndrome in London, Canada.
White KP; Speechley M; Harth M; Ostbye T
J Rheumatol; 1999 Apr; 26(4):885-9. PubMed ID: 10229411
[TBL] [Abstract][Full Text] [Related]
9. Comparison of health care use and costs in newly diagnosed and established patients with fibromyalgia.
White LA; Robinson RL; Yu AP; Kaltenboeck A; Samuels S; Mallett D; Birnbaum HG
J Pain; 2009 Sep; 10(9):976-83. PubMed ID: 19556168
[TBL] [Abstract][Full Text] [Related]
10. Healthcare utilization associated with dyspepsia in patients with arthritis.
Zhao SZ; Arguelles LM; Dedhiya SD; Morgan DG
Am J Manag Care; 1999 Oct; 5(10):1285-95. PubMed ID: 10622994
[TBL] [Abstract][Full Text] [Related]
11. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics, pharmacotherapy and healthcare resource use among patients with fibromyalgia newly prescribed gabapentin or pregabalin.
Gore M; Sadosky AB; Zlateva G; Clauw DJ
Pain Pract; 2009; 9(5):363-74. PubMed ID: 19500273
[TBL] [Abstract][Full Text] [Related]
13. Opioid use patterns and health care resource utilization in patients prescribed opioid therapy with and without constipation.
Iyer S; Davis KL; Candrilli S
Manag Care; 2010 Mar; 19(3):44-51. PubMed ID: 20361548
[TBL] [Abstract][Full Text] [Related]
14. Economic cost and epidemiological characteristics of patients with fibromyalgia claims.
Robinson RL; Birnbaum HG; Morley MA; Sisitsky T; Greenberg PE; Claxton AJ
J Rheumatol; 2003 Jun; 30(6):1318-25. PubMed ID: 12784409
[TBL] [Abstract][Full Text] [Related]
15. Clinical comorbidities, treatment patterns, and healthcare costs among patients with fibromyalgia newly prescribed pregabalin or duloxetine in usual care.
Gore M; Tai KS; Chandran A; Zlateva G; Leslie D
J Med Econ; 2012; 15(1):19-31. PubMed ID: 21970699
[TBL] [Abstract][Full Text] [Related]
16. Costs of gastrointestinal events after outpatient opioid treatment for non-cancer pain.
Kwong WJ; Diels J; Kavanagh S
Ann Pharmacother; 2010 Apr; 44(4):630-40. PubMed ID: 20197473
[TBL] [Abstract][Full Text] [Related]
17. Depression and fibromyalgia: treatment and cost when diagnosed separately or concurrently.
Robinson RL; Birnbaum HG; Morley MA; Sisitsky T; Greenberg PE; Wolfe F
J Rheumatol; 2004 Aug; 31(8):1621-9. PubMed ID: 15290744
[TBL] [Abstract][Full Text] [Related]
18. Real-world evaluation of health-care resource utilization and costs in employees with fibromyalgia treated with pregabalin or duloxetine.
Harnett J; Margolis J; Cao Z; Fowler R; Sanchez RJ; Mardekian J; Silverman SL
Pain Pract; 2011; 11(3):217-29. PubMed ID: 21199319
[TBL] [Abstract][Full Text] [Related]
19. The economic burden of lung cancer and the associated costs of treatment failure in the United States.
Kutikova L; Bowman L; Chang S; Long SR; Obasaju C; Crown WH
Lung Cancer; 2005 Nov; 50(2):143-54. PubMed ID: 16112249
[TBL] [Abstract][Full Text] [Related]
20. Effects of fluticasone propionate/salmeterol combination on asthma-related health care resource utilization and costs and adherence in children and adults with asthma.
Delea TE; Hagiwara M; Stanford RH; Stempel DA
Clin Ther; 2008 Mar; 30(3):560-71. PubMed ID: 18405796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
